

Global Medical Device Company and Leader in the Treatment of Cardiovascular Diseases

- Over 3,500 employees
- 1 million patients treated with the Sorin Group's devices every year in over 80 countries
- Over 5,000 hospitals served around the world
- Listed on the Italian Stock Exchange (MIL:SRN)

3 Strategic Therapeutic Areas

Cardiopulmonary

- Heart- lung machines, oxygenators, autotransfusion systems when extracorporeal circulation is needed during prosthetic replacement, bypass, valve repair


Cardiac Rhythm Management (CRM)

- Implantable cardiac defibrillator (ICD) and pacemaker systems to restore normal cardiac rhythm, cardiac resynchronization therapy (CRT) systems to treat heart failure and holter systems

Heart Valves

- Tissue and mechanical valves, annuloplasty rings for prosthetic replacement and valve repair

Sorin Group Sales - 2008 Results by Strategic Therapeutic Area



Foundation of Sorin Group

- Northern Italy, 1956
- Founded in response to the challenge of nuclear energy production
- The name SORIN comes from the initials: "Societa Ricerche Impianti Nucleari"
- During the 1960's the technical know-how acquired in a wide range of scientific fields was refocused into the biomedical sector
- 1964: First Sorin Group pacemaker implant

FIRST TO IMAGINE. FIRST TO INVENT

At Sorin CRM we encourage imagination. FIRST TO IMAGINE, FIRST TO INVENT embodies creativity through applied engineering excellence. Translating our imagination into clinically meaningful technology, we concentrate on what we do best: Cardiac Rhythm Management systems imagined, designed, built to improve and save lives.

2008	World's FIRST implant of PARADYM™ sonR™ 8770 for continuous hemodynamic adjustment of CRT ^{4,5}
2007	World's smallest dual chamber pacemaker: REPLY™ with SafeR™ ³
2005	World's smallest ICD: OVATIO™ ³ DR 6550, VR 6250
2003	World's FIRST pacing mode to maintain 99.9% intrinsic conduction ¹ : AAsafeR™ ²
2002	World's FIRST sensor to optimize AV & VV delay
1995	World's FIRST dual chamber defibrillator implant: DEFENDER®
1994	World's FIRST implant of a bi-ventricular pacing system
1981	World's FIRST microcomputer within a pacemaker

1. AAsafeR in Symphony® DR 2550 pacemakers. "99.9% intrinsic AV conduction in 28/35 (80%) of patients of non-selected DDD patients" Anselme, F., et al. First clinical results of AAsafeR2, a new mode to prevent ventricular pacing. Heart Rhythm 2005; 2, supp 5; p4-99 (abs).

2. CE mark granted in 2003, FDA approval in 2005.

3. September 2008 data.

4. 2009 Planned launch. Not available for distribution.

5. REF 1: "Continuous monitoring of an endocardial index of myocardial contractility during head-up tilt test". Deharo, J-C., et al - Am Heart J 2000; 139:1022-30; REF 2: "Automatic optimization of resting and exercise AV intervals using a PEA sensor" Leung, S-K., et al. - PACE 2000;23:1672-1766.